Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644233 | 0.90 | MAPT (0.40) | MAPTRXFP1HTTKDM4E | |
| SCHEMBL2643554 | 0.87 | MAPT (0.38) | MAPTRXFP1LMNAALDH1A1 | |
| SCHEMBL2643817 | 0.84 | HTT (0.37) | MAPTHTT | |
| SCHEMBL2644689 | 0.84 | MAPT (0.43) | MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL2644438 | 0.83 | MAPT (0.54) | MAPTKDM4E | |
| SCHEMBL2643302 | 0.80 | MAPT (0.38) | MAPTKDM4ELMNAENPP2ALDH1A1 | |
| SCHEMBL2645436 | 0.76 | KDM4E (0.45) | MAPTHTTKDM4ELMNAALDH1A1 | |
| SCHEMBL9071627 | 0.74 | MAPT (0.37) | MAPTHTTKDM4EALDH1A1 | |
| SCHEMBL2643060 | 0.74 | KCNH2 (0.40) | MAPTKDM4EALDH1A1 | |
| SCHEMBL2645468 | 0.74 | MEN1 (0.51) | MAPTHTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| CN-101316836-A | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | CN | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | MAPT 3322/4885RXFP1 3613/4885HTT 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.